Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Biotechnology

Healthcare
$37.75 -0.55%

-$0.29 today

Market cap
$3.71B
Beta
0.63
P/E (TTM)
-12.1
EPS (TTM)
-$4.39
52W Low $30.00High $63.95

Volume 1.30M

Average 1.16M

XENE Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Xenon Pharmaceuticals Inc.NASDAQ: XENE

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables growth accelerates

Q3 FY2026 accounts receivables of $462K rose 63.3% year over year, ahead of the -192.1% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -61.0% a year.

Context

  • Accounts receivables amounted to 1.4% of revenue in FY2025.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +63.3% holds above the trailing-twelve-month pace of -192.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$462K+325.4% QoQ
Last fiscal yearDec 2025
$104K+116.9% YoY
LTMSep 2026
-$106.87K-192.1% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+63.3%——
1 year+116.9%——
3-year CAGR-61.0%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
104K USD
Year-over-year change
+116.9%

Accounts Receivables vs competitors

How XENE compares with its peers on the latest reported figures

  • XENE's LTM Sep 2026 accounts receivables of $106.87K is the 8th largest of the 11 companies compared; the peer median is $20.87M.
  • Its year-over-year change of -192.1% is the 6th highest of 7, against a peer median of -2.2%.
  • Over three fiscal years its annual growth of -61.0% compares with a peer median of +9.1%.
XENE Competitors Peer median
Accounts Receivables for XENE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$197.5M -20.0%+9.1%5.3%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$78.63M +0.2%+29.8%10.1%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$47.41M -506.5%+10.9%5.7%
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$46.65M +402.0%—4.1%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$37.81M -4.5%+5.6%0.8%
DNLIDenali Therapeutics Inc.LTM Jun 2026$3.93M ——109.0%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$1.71M +72.7%-34.9%—
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$106.87K -192.1%-61.0%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$58K ——0.3%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$0 ———
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding XENE) $20.87M-2.2%+9.1%5.3%

Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(78.88M)(125.37M)(182.39M)(234.33M)(345.91M)
Depreciation & Amortization906K1.41M3.54M2.56M2.54M
Deferred Income Tax58K(44K)(292K)(8.86M)(3.2M)
Stock-Based Compensation10.02M20.38M32.37M50.72M53.71M
Change in Working Capital(2.65M)(676K)5.64M5.71M4.36M
Accounts Receivables(459K)1.76M130K(614K)104K
Inventory(2.97M)0000
Accounts Payables2.97M8.06M3.93M8.53M5.51M
Other Working Capital(2.19M)(10.5M)1.57M(2.2M)(1.26M)
Other Non-Cash Items1.05M5.88M(4.19M)2.82M9.38M
Operating Cash Flow(69.5M)(98.43M)(145.33M)(181.39M)(279.12M)
Capital Expenditures(2.05M)(2.89M)(5.62M)(3.08M)(799K)
Acquisitions (Net)(144.75M)296M000
Purchases of Investments(389.47M)(551.14M)(793.91M)(532.27M)(355.66M)
Sales of Investments144.75M258.03M682.35M700.34M574.45M
Other Investing Activities144.75M(296M)000
Investing Cash Flow(246.77M)(296M)(117.17M)165M218M
Debt Repayment00000
Common Stock Issued447.28M277.77M353.49M12.08M117.11M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities260K705K35K47K0
Financing Cash Flow447.54M278.47M353.52M12.13M117.11M
Effect of Forex Changes(592K)(2.48M)376K(1.67M)458K
Net Change in Cash130.68M(118.45M)91.4M(5.93M)56.45M
Free Cash Flow(71.55M)(101.32M)(150.94M)(184.46M)(279.92M)

Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Intrinsic Alpha fair value

Locked

Current Price

$37.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.